Orbis header
Orbis Mobile

LGM Pharma is a proud supplier of API’s to Orbis Biosciences for the use in their Precision Particle Fabrication® technology for controlled released drug formulations.

Orbis Biosciences’ goal is to revolutionize the delivery, efficacy, and safety of pharmaceutical products through unprecedented control of particle size, composition and release kinetics.

orbis-image-1

We leverage world class talent and the most useful controlled release technology available today to achieve that goal.

Our Precision Particle Fabrication® technology produces uniform microspheres and microcapsules with narrow size distribution and precise control over particle structure. That means new ways to improve and differentiate your products, including their delivery, efficacy, and safety.

Other vibratory technologies fall short because the smallest achievable particle size is governed by the orifice diameter.

Orbis specializes in creating novel solutions for taste masking, extended release oral suspensions, and enteric-coated powders using the Optimμm® microencapsulation technology and solutions for pulsatile release and extended release injectable formulations using the Stratμm™ technology.

orbis-image-2Orbis’ Optimμm® microencapsulation technology offers significant advantages for pediatric and geriatric drug reformulations. The simple, robust, and precise particle engineering allows for an unprecedented amount of control over the final product, which improves dosing efficiency and efficacy and reduces adverse effects.

This highly-flexible and customizable encapsulation platform provides a convenient means of masking the bitter flavor of many drugs while also establishing a delivery system that is adaptable to many patient-friendly formats including oral liquid suspensions, powders, dispersible tablets, chewable tablets, and injectable suspensions.

orbis-image-3

Leveraged for injectable pharmaceuticals, the Stratμm™ technology provides controlled release technology solutions for extended release formulations (continuous release for weeks, months, years).

For extended release applications, Stratμm’s uniform particles provide release accuracy for narrow therapeutic index drugs and minimize the initial drug burst for increased safety and efficacy.

The batch-to-batch reproducibility is critical for achieving precise release profiles. The Stratμm™ technology is highly scalable and has the ability to create microspheres in a single step. The novel nature of the products and the cost-effective approach lend itself to creating the injectable products of tomorrow.

For more information regarding the capabilities of Orbis Biosciences and their Precision Particle Fabrication® technology please contact them at info@orbisbio.com or contact the team at LGM to discuss your API requirements. 

Other Featured Clients in Action

Opertech Bio is a service-based business offering its customers a pioneering approach to measuring taste, covering the food and beverage, flavor ingredients, pet food, and pharmaceutical industries. Learn More >

Illustris is a clinical-stage biodevelopment company whose objective is to reduce society’s exposure to potentially harmful active agents by utilizing our novel permeation technology to deliver active agents through tissue structures more efficiently. Learn More >

LGM Pharma is a proud supplier of API’s to Orbis Biosciences for the use in their Precision Particle Fabrication® technology for controlled released drug formulations.

Orbis Biosciences’ goal is to revolutionize the delivery, efficacy, and safety of pharmaceutical products through unprecedented control of particle size, composition and release kinetics.

orbis-image-1

We leverage world class talent and the most useful controlled release technology available today to achieve that goal.

Our Precision Particle Fabrication® technology produces uniform microspheres and microcapsules with narrow size distribution and precise control over particle structure. That means new ways to improve and differentiate your products, including their delivery, efficacy, and safety.

Other vibratory technologies fall short because the smallest achievable particle size is governed by the orifice diameter.

Orbis specializes in creating novel solutions for taste masking, extended release oral suspensions, and enteric-coated powders using the Optimμm® microencapsulation technology and solutions for pulsatile release and extended release injectable formulations using the Stratμm™ technology.

orbis-image-2Orbis’ Optimμm® microencapsulation technology offers significant advantages for pediatric and geriatric drug reformulations. The simple, robust, and precise particle engineering allows for an unprecedented amount of control over the final product, which improves dosing efficiency and efficacy and reduces adverse effects.

This highly-flexible and customizable encapsulation platform provides a convenient means of masking the bitter flavor of many drugs while also establishing a delivery system that is adaptable to many patient-friendly formats including oral liquid suspensions, powders, dispersible tablets, chewable tablets, and injectable suspensions.

orbis-image-3

Leveraged for injectable pharmaceuticals, the Stratμm™ technology provides controlled release technology solutions for extended release formulations (continuous release for weeks, months, years).

For extended release applications, Stratμm’s uniform particles provide release accuracy for narrow therapeutic index drugs and minimize the initial drug burst for increased safety and efficacy.

The batch-to-batch reproducibility is critical for achieving precise release profiles. The Stratμm™ technology is highly scalable and has the ability to create microspheres in a single step. The novel nature of the products and the cost-effective approach lend itself to creating the injectable products of tomorrow.

For more information regarding the capabilities of Orbis Biosciences and their Precision Particle Fabrication® technology please contact them at info@orbisbio.com or contact the team at LGM to discuss your API requirements. 

Other Featured Clients in Action

Opertech Bio is a service-based business offering its customers a pioneering approach to measuring taste, covering the food and beverage, flavor ingredients, pet food, and pharmaceutical industries. Learn More >

Illustris is a clinical-stage biodevelopment company whose objective is to reduce society’s exposure to potentially harmful active agents by utilizing our novel permeation technology to deliver active agents through tissue structures more efficiently. Learn More >

This website uses cookies. By using our site, you agree to our terms of service